URGN — UroGen Pharma Ltd.

UroGen Pharma Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $72.5 million, a significant increase from $24.2 million in Q2 2025, primarily driven by the launch of ZUSDURI.
• ZUSDURI Revenue: $50.4 million, representing a 73% growth from Q1 2026.
• JELMYTO Revenue: $22 million, slightly up from $21.7 million in Q1 2026.
• Net Loss: $14.4 million or $0.28 per share, improved from a net loss of $49.9 million or $1.05 per share in Q2 2025.
• Cash Position: $108 million in cash, cash equivalents, and marketable securities as of June 30, 2026.
• Operating Expenses: Increased to $48.4 million, driven by ZUSDURI commercial activities.

2. Strategic Updates and Business Highlights

• ZUSDURI Launch: Continued momentum with 1,444 activated accounts and 452 unique prescribers, indicating strong adoption in both hospital and community practices.
• Community Practices: Approximately 55% of ZUSDURI utilization is now in community settings, which represent about 70% of the addressable market.
• Reimbursement: Open access across 95% of covered lives, with no significant barriers to adoption.
• Intellectual Property: Settlement with Teva regarding JELMYTO patent litigation and a new method of treatment patent for ZUSDURI and UGN-103 expected to provide protection until July 2044.
• Pipeline Progress: UGN-103 NDA submission anticipated in Q3 2026, with ongoing Phase III trials for UGN-104 and initiation of Phase I for UGN-501 expected this year.

3. Forward Guidance and Outlook

• JELMYTO Revenue Guidance: Expected to be between $97 million and $101 million for 2026, reflecting 3% to 7% growth over 2025.
• ZUSDURI Guidance: No formal revenue guidance provided yet due to the early stage of the launch; guidance may be issued in 2027.
• Operating Expense Guidance: Increased to $260 million to $270 million for 2026, reflecting investments in ZUSDURI and pipeline development.

4. Bad News, Challenges, or Points of Concern

• Market Adoption: Despite strong growth, the company acknowledges that urologists are traditionally slow to adopt new therapies, which may limit rapid uptake.
• Competition: The competitive landscape is intensifying, particularly with other therapies emerging in the bladder cancer space.
• JELMYTO Performance: No significant "halo effect" observed from ZUSDURI on JELMYTO uptake, indicating that the two products may not be mutually beneficial in terms of sales growth.

5. Notable Q&A Insights

• Community Practices: The company sees significant potential in community practices but acknowledges the challenges in operationalizing ZUSDURI in these settings.
• Adoption Metrics: Physicians are increasingly using ZUSDURI for a broader range of patients, not just those ineligible for surgery, indicating growing confidence in the product.
• Profitability Outlook: Management remains confident in reaching profitability with existing capital resources despite increased spending on growth initiatives.
• Competitive Positioning: UGN-103 is expected to provide a competitive edge in the high-risk NMIBC market, with a focus on its unique delivery mechanism and safety profile.

Overall, UroGen Pharma reported a strong quarter with significant revenue growth driven by the ZUSDURI launch, while also outlining strategic initiatives to enhance market penetration and pipeline development. However, challenges remain in market adoption and competition, which the company is actively addressing.